<DOC>
	<DOCNO>NCT02276508</DOCNO>
	<brief_summary>Nissle 1917 E. coli base probiotic use Europe close 100 year treat gastrointestinal disorder infection . The investigator assess safety tolerability medication Americans Phase 1 trial .</brief_summary>
	<brief_title>Open Label Trial Nissle 1917</brief_title>
	<detailed_description>Background : Nissle 1917 E. coli base probiotic successfully use Europe close 100 year treat largely gastrointestinal disorder like inflammatory bowel disease , gastroenteritis , irritable bowel syndrome . In addition disorder , believe Nissle 1917 promise alternative therapy prevention urinary tract infection susceptible individual . Purpose : The Phase 1 trial use Nissle 1917 healthy adult patient volunteer first time United States . The investigator track frequency incidence side effect adverse event . Participants : 20 adult ( &gt; 21 year age ) healthy volunteer Protocol : - Participants enroll trial review medical history physical . - Participants take 30 day course Nissle 1917 capsule - Investigators telephone participant 1-2 week begin trial assess side effect adverse event - Subjects also provide diary record side effect adverse event - At end 30 day , participant return clinic follow visit discuss side effect adverse event experience trial return unused medication - Investigators telephone participant 28-35 day follow completion study drug pose questionnaire aim revealing side effect adverse event .</detailed_description>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<criteria>Healthy adult volunteer age 21 year old Any individual active urinary tract infection ( UTI ) Any individual acute illness within past 7 day Any individual neurogenic bladder vesicoureteral reflux Any individual anatomic abnormality , congenital acquire , urinary tract system Any individual anatomic abnormality , congenital acquire , gastrointestinal tract Any individual untreated dysfunctional elimination syndrome Immunocompromised patient Individuals central venous catheter Individuals require use antibiotic , immunomodulatory medication , probiotic Any participant history chronic gastrointestinal disease Any individual chronic uncontrolled medical illness Any female reproductive age currently pregnant , breastfeeding , sexually active unwilling unable use acceptable method contraception . Any participant unable appropriately take store medication Any individual enrol clinical trial evaluate another investigational agent last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>